scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001975561 |
P356 | DOI | 10.1186/1479-5876-9-168 |
P932 | PMC publication ID | 3198929 |
P698 | PubMed publication ID | 21970318 |
P5875 | ResearchGate publication ID | 51692856 |
P50 | author | Claudia Alexandra Dumitru | Q66360856 |
Robert L Ferris | Q38328358 | ||
Sven Brandau | Q39436389 | ||
P2093 | author name string | Theresa L Whiteside | |
Stephan Lang | |||
Pedro A Andrade Filho | |||
Edwin Boelke | |||
Goetz F Lehnerdt | |||
Jens Greve | |||
Murat Bas | |||
Patrick J Schuler | |||
Petra Boeckers | |||
Rainer Engers | |||
Thomas K Hoffmann | |||
P2860 | cites work | Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. | Q52012168 |
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex | Q73205726 | ||
Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes | Q79819764 | ||
Lead and follow: the dance of the dendritic cell and T cell | Q81020106 | ||
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion | Q35125791 | ||
Signaling through the epidermal growth factor receptor during the development of malignancy | Q35729447 | ||
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer | Q36526586 | ||
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer | Q36613924 | ||
Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients | Q36962838 | ||
Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer | Q37040545 | ||
Tricks tumors use to escape from immune control | Q37495211 | ||
A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration | Q39885205 | ||
T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx | Q40351911 | ||
Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. | Q40500501 | ||
High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. | Q40848769 | ||
Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. | Q41715382 | ||
Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells | Q44987437 | ||
A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs | Q45086654 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 168 | |
P577 | publication date | 2011-10-04 | |
P1433 | published in | Journal of Translational Medicine | Q15716664 |
P1476 | title | EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma | |
P478 | volume | 9 |
Q50043038 | CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer |
Q36806268 | Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients |
Q28069424 | Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment |
Q45770749 | Immunotherapy of head and neck cancer. Current developments |
Q38162129 | Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer |
Q90390338 | OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity |
Q36883848 | Promising systemic immunotherapies in head and neck squamous cell carcinoma |
Q33872482 | Targeting CD137 enhances the efficacy of cetuximab. |
Q38821915 | Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma |
Q38161874 | The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities |
Q36476100 | Trial watch: Peptide vaccines in cancer therapy |
Search more.